Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 1
2005 1
2011 1
2015 3
2016 3
2017 3
2018 3
2019 3
2020 3
2021 2
2022 4
2023 3
2024 4
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS; ISABELA 1 and 2 Investigators. Maher TM, et al. JAMA. 2023 May 9;329(18):1567-1578. doi: 10.1001/jama.2023.5355. JAMA. 2023. PMID: 37159034 Free PMC article.
Acute exacerbations in patients with progressive pulmonary fibrosis.
Kreuter M, Belloli EA, Bendstrup E, Cerri S, Flaherty KR, Shapera S, Song JW, Mueller H, Rohr KB, Kondoh Y; INBUILD trial investigators. Kreuter M, et al. Among authors: belloli ea. ERJ Open Res. 2024 Dec 2;10(6):00403-2024. doi: 10.1183/23120541.00403-2024. eCollection 2024 Nov. ERJ Open Res. 2024. PMID: 39624387 Free PMC article.
A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis.
Wang JM, Adegunsoye A, Pugashetti JV, Lee CT, Murray S, Mohan N, Nazemi N, Kang E, Chelala L, Kazerooni EA, Flaherty KR, Belloli EA, Sheth JS, O'Dwyer DN, Strek ME, Hatt CR, Han MK, Chung JH, Oldham JM. Wang JM, et al. Among authors: belloli ea. Am J Respir Crit Care Med. 2025 Oct;211(10):1785-1793. doi: 10.1164/rccm.202501-0208OC. Am J Respir Crit Care Med. 2025. PMID: 40680162 Free PMC article.
Idiopathic non-specific interstitial pneumonia.
Belloli EA, Beckford R, Hadley R, Flaherty KR. Belloli EA, et al. Respirology. 2016 Feb;21(2):259-68. doi: 10.1111/resp.12674. Epub 2015 Nov 13. Respirology. 2016. PMID: 26564810 Free article. Review.
Update in Interstitial Lung Disease 2014.
Belloli EA, Martinez FJ, Flaherty KR. Belloli EA, et al. Am J Respir Crit Care Med. 2015 Sep 1;192(5):538-43. doi: 10.1164/rccm.201504-0768up. Am J Respir Crit Care Med. 2015. PMID: 26561676 Review. No abstract available.
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis.
Newton CA, Thenappan A, Liu GY, Yazbeck L, Lee CT, Pugashetti JV, Wang JM, White E, Flaherty KR, Belloli EA, Sheth JS, Mohan N, Nazemi N, Yu AR, Ghodrati S, Johannson KA, Marcoux V, Fisher JH, Assayag D, Manganas H, Khalil N, Kolb M, Morisset J, Garcia CK, Chua F, Strek ME, Khor YH, Adegunsoye A, Ryerson CJ, Molyneaux PL, Oldham JM. Newton CA, et al. Among authors: belloli ea. Am J Respir Crit Care Med. 2025 Oct;211(10):1867-1875. doi: 10.1164/rccm.202501-0317OC. Am J Respir Crit Care Med. 2025. PMID: 40530983
37 results